Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer
Patients with prostate cancer treated in outpatient clinics will be recruited by their urologist physician.
To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon recommendation by Urologists.
To evaluate the overall number of patients treated by Bisphosphonate in the out-patient clinics, To evaluate incidence of osteopenia/osteoporosis in this study population.
Observational Model: Cohort, Time Perspective: Prospective
Sanofi-aventis administrative office
Active, not recruiting
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT00816452
- Information obtained from ClinicalTrials.gov on July 15, 2010
We wish to investigate whether a weekly, 2½ hour group-based osteoporosis education intervention (the Osteoporosis Prevention and Self-Management Course), is different to one session cour...
The goals of the trial are: - To determine the prevalence of osteoporosis in subgroups of COPD patients. - To look for risk factors of osteoporosis in COPD patients. - To...
Osteoporosis or "thinning of the bones" affects in 1 in 4 Canadian women and 1 in 8 Canadian men. Moreover, while the rates of osteoporosis among Canadians are stabilizing, worldwide the ...
The aim of the ROCQ programme is to improve the use of evidence based osteoporosis diagnostic and treatment strategies for women 50 years and over who have suffered a fragility fracture. T...
The aim of this research registry is to collect information on individuals with osteoporosis, those with risk factors for osteoporosis, and comparative healthy controls. Bone mineral densi...
A programmatic outpatient high-risk osteoporosis clinic (outpatient HiROC) and inpatient fracture liaison service (inpatient HiROC) is described. Results document that this population is more effectiv...
Osteoporosis is a highly prevalent yet preventable disease. Nurses can play a major role in the prevention of osteoporosis and preventive treatment of patients who have had an osteoporotic fracture.
The prevalence of osteoporosis is increasing and is a socio-economic burden worldwide. Although screening tests for osteoporosis in Korea are easily accessible, this condition remains undertreated. Ev...
Long-term persistence with anti-osteoporosis drugs and determinants for discontinuation among fracture patients were examined. Persistence was 75.0 and 45.3 % after 1 and 5 years, respectively. Thos...
Medical and Biotech [MESH] Definitions
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
The mineral component of bones and teeth; it has been used therapeutically as a prosthetic aid and in the prevention and treatment of osteoporosis.
Breaks in bones resulting from low bone mass and microarchitectural deterioration characteristic of OSTEOPOROSIS.
A condition of competitive female athletes in which there are interrelated problems of EATING DISORDERS; AMENORRHEA; and OSTEOPOROSIS.